An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) reaffirms its commitment to raising awareness about lupus nephritis (LN) during Lupus Awareness Month. The company is engaging in various education initiatives to improve understanding, screening, and management of LN. Through partnerships and advocacy efforts, Aurinia aims to eliminate barriers to access, promote equity, and enhance health outcomes for individuals affected by LN.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) ribadisce il suo impegno nel sensibilizzare riguardo la nefrite lupica (LN) durante il Mese di Sensibilizzazione sul Lupus. L'azienda sta partecipando a diverse iniziative educative per migliorare la comprensione, la diagnosi e la gestione della LN. Attraverso partnership e sforzi di advocacy, Aurinia mira a eliminare gli ostacoli all'accesso, promuovere l'equità e migliorare gli esiti sanitari per le persone affette da LN.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) reafirma su compromiso con la concienciación sobre la nefritis lúpica (LN) durante el Mes de Concienciación sobre el Lupus. La compañía está involucrada en varias iniciativas educativas para mejorar la comprensión, el cribado y el manejo de la LN. A través de asociaciones y esfuerzos de defensa, Aurinia busca eliminar las barreras de acceso, promover la equidad y mejorar los resultados de salud para los individuos afectados por LN.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH)는 루푸스 인식의 달 동안 루푸스 신염(LN)에 대한 인식을 높이기 위해 그 결심을 재확인합니다. 이 회사는 LN의 이해, 선별 및 관리를 개선하기 위해 여러 교육 이니셔티브에 참여하고 있습니다. 파트너십과 옹호 노력을 통해 Aurinia는 접근 장벽을 제거하고, 형평성을 증진하며, LN으로 영향을 받는 개인의 건강 결과를 향상시키기를 목표로 합니다.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) réaffirme son engagement à sensibiliser le public à la néphrite lupique (LN) lors du Mois de sensibilisation au lupus. L'entreprise participe à diverses initiatives éducatives pour améliorer la compréhension, le dépistage et la gestion de la LN. À travers des partenariats et des efforts de plaidoyer, Aurinia vise à éliminer les obstacles à l'accès, promouvoir l'équité et améliorer les résultats de santé pour les personnes affectées par la LN.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) bekräftigt sein Engagement, das Bewusstsein für Lupusnephritis (LN) während des Lupus-Bewusstseinsmonats zu erhöhen. Das Unternehmen beteiligt sich an verschiedenen Bildungsinitiativen, um das Verständnis, das Screening und das Management von LN zu verbessern. Durch Partnerschaften und Advocacy-Bemühungen zielt Aurinia darauf ab, Zugangsbarrieren zu beseitigen, Gleichheit zu fördern und die Gesundheitsergebnisse für von LN betroffene Personen zu verbessern.
Positive
None.
Negative
None.
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--
In recognition of Lupus Awareness Month, Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced several initiatives to improve understanding of the seriousness of lupus nephritis (LN) and the need for frequent screening and appropriate management, including an innovative disease state education campaign for rheumatologists.
Aurinia is on a mission to tackle the toughest challenges that the LN community faces through collaborative efforts with key stakeholders across the healthcare ecosystem, including patients, healthcare professionals (HCPs), and policymakers. Through awareness, education, advocacy, and partnerships with the LN community, the Aurinia team is working to help eliminate barriers to access, promote equity, and improve health outcomes for those impacted by LN.
“Since its inception, Aurinia has stood tall as a dedicated leader in overtaking one of the toughest challenges in autoimmune disease – lupus nephritis,” said Peter Greenleaf, Chief Executive Officer of Aurinia. “We are actively engaged in ongoing clinical research and educational initiatives supporting both patients and healthcare professionals, striving to improve LN screening, diagnosis, and management. We recognize the importance of collaborating with the LN community in all our efforts, and we remain committed to listening to their perspectives at every stage of our journey.”
To further its education and advocacy efforts, Aurinia has several key initiatives throughout Lupus Awareness Month and the rest of the year:
Know the Signs Campaign
Aurinia recently launched a disease state education campaign for rheumatologists aimed at improving health outcomes for people with LN through education around the signs of LN and the importance of kidney health. The campaign is designed to increase awareness among rheumatologists around the severity of LN, increase awareness among HCPs around the vitality of prioritizing kidney health for people with systemic lupus erythematosus (SLE), and increase screening for LN among people with SLE.
Lupus Call to Action Day
Aurinia is supporting the National Minority Health Association for its Lupus Call to Action Day on May 1, 2024, in New York City. The event will feature interviews and conversations with healthcare stakeholders and others in the lupus community to drive awareness and discuss challenges and ways to improve health equity among people with lupus and lupus nephritis – including Grammy-award-winning artist, Toni Braxton who will share her personal lupus journey as part of her partnership with Aurinia and the Get Uncomfortable for Lupus Nephritis campaign. The event will be live streamed by BlackDoctor.org. Visit the BlackDoctor.org Facebook page to tune into the event.
Advocacy Events
As a dedicated partner to the LN community, Aurinia participates in events across the country throughout the year to promote awareness and uplift the people living with LN. In May, Aurinia will attend the Lupus Research Alliance LuCIN Meeting in San Diego, CA, May 9-11; World Lupus Day, including the Lupus and Allied Diseases Association Tea Party, May 10; Aurinia Legislative Townhall in Tampa, FL, May 18; and the Lupus Foundation of America Advocacy Day in Washington, D.C., May 19-21.
About Lupus Nephritis
Lupus Nephritis is a serious manifestation of systemic lupus erythematosus (SLE), a chronic and complex autoimmune disease. About 200,000-300,000 people live with SLE in the U.S., and about one-third of these people are diagnosed with lupus nephritis at the time of their SLE diagnosis. About 50 percent of all people with SLE may develop lupus nephritis. If poorly controlled, lupus nephritis can lead to permanent and irreversible tissue damage within the kidney. Black and Asian people with SLE are four times more likely to develop lupus nephritis and Hispanic people are approximately twice as likely to develop the disease, compared to White people with SLE. Black and Hispanic people with SLE also tend to develop lupus nephritis earlier and have worse outcomes, compared to White people with SLE.
About Aurinia
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations with high unmet medical needs that are impacted by autoimmune, kidney and rare diseases. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. The Company’s head office is in Edmonton, Alberta, its U.S. commercial office is in Rockville, Maryland. The Company focuses its development efforts globally.
What initiatives did Aurinia announce for Lupus Awareness Month?
Aurinia announced several initiatives to improve understanding of lupus nephritis (LN), including a disease state education campaign for rheumatologists.
Who will share their personal lupus journey as part of the Get Uncomfortable for Lupus Nephritis campaign?
Grammy-award-winning artist Toni Braxton will share her personal lupus journey as part of her partnership with Aurinia.
When is Lupus Call to Action Day taking place?
Lupus Call to Action Day will be held on May 1, 2024, in New York City.
What advocacy events will Aurinia participate in during May?
Aurinia will attend various events in May, including the Lupus Research Alliance LuCIN Meeting, World Lupus Day, Aurinia Legislative Townhall, and the Lupus Foundation of America Advocacy Day.
